DexCom Company Profile (NASDAQ:DXCM)

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

DexCom, Inc. (NASDAQ:DXCM) posted its earnings results on Tuesday, May, 2nd. The company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.06. The company had revenue of $142.30 million for the quarter, compared to the consensus estimate of $143.94 million. DexCom had a negative return on equity of 32.94% and a negative net margin of 14.70%. View DexCom's Earnings History.

DexCom is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for DexCom.

18 brokers have issued 1 year target prices for DexCom's shares. Their predictions range from $66.00 to $105.00. On average, they expect DexCom's stock price to reach $89.47 in the next year. View Analyst Ratings for DexCom.

Here are some recent quotes from research analysts about DexCom stock:

• 1. According to Zacks Investment Research, "In the past one year, DexCom has underperformed the broader industry in terms of price. Furthermore, a disappointing estimate revision trend indicates looming concerns ahead. DexCom reported narrower-than-expected loss in the first quarter. We believe the company’s margins will continue to be under pressure in the coming quarters owing to high product development costs and rising expenditures on research & development. Specifically, the company is expected to have lower margins on transmitter sales (in spite of the cost reduction initiatives). Additionally, cutthroat competition in the market for blood glucose monitoring devices is a major headwind. On the positive side, the glucose monitoring market represents significant commercial opportunity for DexCom. The company has also signed collaborative agreements with several companies, which should not only bring in cash but also help expand its product portfolio." (7/18/2017)
• 2. Jefferies Group LLC analysts commented, "DXCM reported 4Q sales $3mn ahead of its pre-announcement. Guidance for 2017 remained +25-30% ($710-740mn); importantly, this considers competitive entries by MDT (670G) and ABT (Libre), but does not factor in any contribution from DXCM patients covered by Medicare. With this low bar set for 2017, the next-gen G6 and the Verily Type 2 system coming in 2018, DXCM remains well positioned to succeed in an evolving diabetes landscape. The stock remains a top idea." (3/1/2017)
• 3. BTIG Research analysts commented, "Most Important; But The Report Was Not Clean; Buy As we previewed, revenue of $137.3M was in-line with our estimate and well above the street. We think this is most important. GMs disappointed and the $10M guidance raise was likely less than some hoped. With the stock having run from the $60s to the $90s, it is not surprising to see it pull back to the mid $80s afterhours. We would opportunistically buy shares on dips and would become aggressive around $80.   Top-line growth continues to beat expectations, thesis remains the same though in the $80s, upside has moderated. Having crushed both Q1 and Q2 sales expectations, we see DXCM as meeting our growth thesis. We believe some expected a raise beyond the new $550-$575M FY16 guidance. While this may pressure shares tomorrow we note during Q&A, mgmt did discuss how they would be pleased to come in above this when asked about $575-$600M. We model above guidance with $581M for Fy16." (8/4/2016)

Some companies that are related to DexCom include Steris Plc (STE), Bio-Rad Laboratories (BIO), West Pharmaceutical Services (WST), Hill-Rom Holdings (HRC), VWR Corporation (VWR), Integra LifeSciences Holdings Corporation (IART), NuVasive (NUVA), ICU Medical (ICUI), LivaNova PLC (LIVN), Nevro Corp. (NVRO), Neogen Corporation (NEOG), Haemonetics Corporation (HAE), Inogen (INGN), Halyard Health (HYH), MiMedx Group (MDXG), CONMED Corporation (CNMD), Asante Solutions (PUMP) and K2M Group Holdings (KTWO).

DexCom's management team includes the folowing people:

• Terrance H. Gregg, Executive Chairman of the Board
• Kevin R. Sayer, President, Chief Executive Officer, Director
• Kevin M. Sun, Interim Chief Financial Officer
• Donald Abbey, Executive Vice President, Quality and Information Technology
• Andrew K. Balo, Executive Vice President - Clinical, Regulatory and Quality
• Richard B. Doubleday, Executive Vice President, Chief Commercial Officer
• Steven R. Pacelli, Executive Vice President - Strategy and Corporate Development
• Heather Ace, Senior Vice President, Human Resources
• Jake Leach, Senior Vice President of Research and Development
• Jeffrey C. Moy, Senior Vice President - Operations

DexCom's stock is owned by many different of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (0.37%), Rothschild Capital Partners LLC (0.07%), Chevy Chase Trust Holdings Inc. (0.05%), Patten & Patten Inc. TN (0.05%), Bank of Montreal Can (0.04%) and Sit Investment Associates Inc. (0.03%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jess Roper, John Lister, Jonathan T Md Lord, Jorge A Valdes, Kevin R Sayer, Mark G Foletta, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for DexCom.

DexCom's stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Shell Asset Management Co., OLD National Bancorp IN, Bremer Trust National Association, Patten & Patten Inc. TN, Sumitomo Mitsui Asset Management Company LTD and BB&T Corp. Company insiders that have sold DexCom stock in the last year include Andrew K Balo, Barbara Kahn, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jess Roper, John Lister, Jonathan T Md Lord, Jorge A Valdes, Kevin R Sayer, Mark G Foletta, Richard Doubleday, Steven Robert Pacelli and Terrance H Gregg. View Insider Buying and Selling for DexCom.

DexCom's stock was acquired by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Bank of Montreal Can, Handelsbanken Fonder AB, Mn Services Vermogensbeheer B.V., US Bancorp DE, Sit Investment Associates Inc., Fox Run Management L.L.C. and Chevy Chase Trust Holdings Inc.. View Insider Buying and Selling for DexCom.

Shares of DexCom can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of DexCom stock can currently be purchased for approximately $68.75.